Putting High Prices On CBD-Containing Supplements Could Ring Up FTC Scrutiny
Executive Summary
Marketers of CBD supplements with hefty price tags could draw FTC attention even if not making disease claims, says attorney Jonathan Havens. Companies not making claims are “responsible purveyors who want people to educate themselves and not cause trouble by making claims that are not substantiated.”
You may also be interested in...
Canada Is Large Firms' CBD Test Market While US Weighs Allowing Sales
Large beer and beverage firms partner with hemp cultivators to compete in fledgling US CBD-infused beverage market, which is estimated to reach $1.4bn sales by 2023. Many firms are working on R&D or have completed products and are waiting for a clear regulatory pathway from FDA before launch.
FDA Opens CBD Regulatory Path Docket, Warns Firms On Claims Missteps
With public hearing scheduled May 31 and a related public comment period, FDA "is interested in whether there are particular safety concerns that we should be aware of as we consider the FDA’s regulatory oversight and monitoring" of CBD products. Also influencing FDA's consideration is that CBD and other cannabis-derived substances are approved and being studied as drugs products, making their use as dietary ingredients noncompliant with agency regulations.
FDA Clearing CBD As Dietary Ingredient? Legislation More Likely Than Rulemaking
Senate Appropriations subcommittee members add to Capitol Hill's push for FDA to change its current regulatory stance that CBD is deemed noncompliant for use in supplements and food. Commissioner Gottlieb suggests legislation authorizing FDA to allow use of CBD up to certain concentrations in supplements and food products. FDA currently allows sales of food and supplements containing CBD under enforcement discretion.